A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to customers ...

“TheracosBio is committed to increasing access to effective, low-cost medications,” said Brian Connelly, President and CEO of TheracosBio. “We are excited to work with Publix to provide their ...

Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Does it also protect the patient from cardiovascular complications?

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

One of the few new diabetes medications that can be administered orally, vildagliptin seems effective at lowering glycosylated hemoglobin, fasting plasma glucose, and prandial glucose levels.

New State of Type 2 Report in the United States reports that a majority of HCPs surveyed believe continuous glucose monitoring will have the potential to be more impactful on the future of Type 2 ...